<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-6 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-6</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-6</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <p><strong>Paper ID:</strong> paper-e9526bf194eda86aa4a79ce4604019b2a0bd1406</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/e9526bf194eda86aa4a79ce4604019b2a0bd1406" target="_blank">Adjuvant and neoadjuvant treatment of melanoma</a></p>
                <p><strong>Paper Venue:</strong> memo - Magazine of European Medical Oncology</p>
                <p><strong>Paper TL;DR:</strong> Considering the promising results reported so far, neoadjuvant immunotherapy might potentially become the treatment of choice in high-risk melanoma patients with macrometastatic disease in the near future.</p>
                <p><strong>Paper Abstract:</strong> For years, interferon alpha was the sole option in the adjuvant treatment of patients with completely resected melanoma with lymph node metastases and a high risk of disease recurrence, albeit being associated with a relatively low efficacy combined with significant toxicities. After the advent of immunotherapy and targeted therapy in locally advanced or metastatic melanoma at the beginning of the last decade, these therapeutic approaches have meanwhile also shown superior efficacy compared to previously used treatments or observation in the context of adjuvant therapy. Hence, adjuvant targeted or anti-PD1-antibody-based immunotherapy was incorporated into routine clinical practice to reduce the risk of tumor recurrence in affected patients in early 2018. Moreover, modern melanoma therapies are increasingly being investigated in a neoadjuvant setting in analogy to other solid malignancies. Considering the promising results reported so far, neoadjuvant immunotherapy might potentially become the treatment of choice in high-risk melanoma patients with macrometastatic disease in the near future.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e6.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e6.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blank et al. 2018</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A clinical study directly comparing neoadjuvant combined CTLA-4 and PD-1 blockade (ipilimumab + nivolumab) versus adjuvant-only administration in patients with macroscopic stage III melanoma; cited in this review but outcome details are not reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Direct comparative clinical study (neoadjuvant versus adjuvant) reported in Nat Med; exact phase/design not specified in this review</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Combination immunotherapy with ipilimumab (CTLA-4 antibody) + nivolumab (PD-1 antibody); timing compared was neoadjuvant (pre-surgery) administration versus adjuvant (post-surgery) administration. Specific dosing and exact schedule are not provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Macroscopic stage III melanoma (resectable nodal disease); sample size not specified in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>This study is cited in the review as a direct head-to-head comparison of neoadjuvant versus adjuvant combined ipilimumab + nivolumab, but the review does not present the trial's numerical clinical outcome, mechanistic, or safety data; the review references it as a key example of direct comparison.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant and neoadjuvant treatment of melanoma', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e6.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A multicentre, phase 2, randomized, controlled neoadjuvant trial comparing dosing schedules of combined ipilimumab + nivolumab in macroscopic stage III melanoma; identified a regimen with high pathological response and an acceptable safety profile for future neoadjuvant use.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicentre, phase 2, randomized, controlled trial comparing neoadjuvant dosing schedules of combined ipilimumab + nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab dosing schedules were tested; the regimen highlighted in the review was two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg given before surgery, without subsequent adjuvant therapy (i.e., neoadjuvant-only in that arm).</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III melanoma (resectable nodal disease); exact sample size not reported in this review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td>Overall pathological response rate 77% for the selected regimen, including 57% pathological complete responses (pCRs); these rates refer to responses evaluated after the neoadjuvant induction period (reported within first 12 weeks).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td>Grade 3/4 adverse event rate 20% within the first 12 weeks for the two-cycle ipi 1 mg/kg + nivo 3 mg/kg neoadjuvant regimen (no subsequent adjuvant given in that regimen, per review).</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>OpACIN-neo identified a neoadjuvant dosing schedule with high pathological response (77%, 57% pCR) and a lower-than-expected grade 3/4 AE rate (20%), supporting feasibility of neoadjuvant combined immunotherapy; the review does not provide direct randomized outcome comparisons versus adjuvant-only within this trial in numeric form.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant and neoadjuvant treatment of melanoma', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e6.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>INMC pooled analysis (Menzies et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A pooled analysis of six neoadjuvant melanoma trials (total n=184) assessing pathological response rates and early survival outcomes after neoadjuvant induction therapy (targeted or combined immunotherapy), often followed by adjuvant therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>INMC pooled analysis (Menzies et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled analysis of six neoadjuvant clinical trials (prospective neoadjuvant trials pooled), total n = 184 patients who underwent surgery after neoadjuvant induction therapy</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Included neoadjuvant combined targeted therapy (e.g., dabrafenib + trametinib) and combined immunotherapy (ipilimumab + nivolumab); neoadjuvant treatment durations reported across trials typically ranged 3–12 weeks and were frequently followed by adjuvant treatment to a total treatment duration of ~1 year.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable melanoma with macrometastatic nodal disease (AJCC stage IIIB–D in the neoadjuvant trial population); pooled n = 184 (who proceeded to surgery) as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td>Pooled pathological complete response (pCR) rates approximately 50% after combined targeted or combined immunotherapy; example: among 51 patients who achieved pCR after neoadjuvant immunotherapy, no recurrence events were observed at a median follow-up of 10 months.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Favorable early RFS reported for patients treated with neoadjuvant immunotherapy in pooled analysis; specifically, 0 recurrences among 51 patients with pCR at median follow-up 10 months. No direct long-term RFS comparison versus adjuvant-only cohorts is provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td>The review notes toxicity is a particular issue with neoadjuvant combined immunotherapy but does not provide pooled AE rates; specific regimen AE data (e.g., from OpACIN-neo) are given elsewhere in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>The pooled analysis suggests high pCR rates (~50%) after neoadjuvant therapy and that patients achieving pCR had very low early recurrence (0/51 recurrences at median 10 months), implying a potential RFS advantage for neoadjuvant immunotherapy; however, the review does not present a direct, quantitative randomized comparison of neoadjuvant-adjuvant versus adjuvant-only immunotherapy across the pooled data.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Adjuvant and neoadjuvant treatment of melanoma', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma <em>(Rating: 2)</em></li>
                <li>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial <em>(Rating: 2)</em></li>
                <li>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) <em>(Rating: 2)</em></li>
                <li>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma <em>(Rating: 2)</em></li>
                <li>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>